<DOC>
	<DOCNO>NCT01705756</DOCNO>
	<brief_summary>FMF common periodic fever worldwide patient population estimate 150,000 , mainly locate Eastern Mediterranean basin . colchicine establish therapy choice , however , around 20.000 patient worldwide fail respond tolerate therapeutic dos , thereby suffer recurrent debilitating , severe , painful attack peritonitis , pleuritis synovitis risk die reactive amyloidosis .Mutation-induced reduction pyrin/ marenostrin activity think underlie disease lead NALP3 inflammasome activation , thereby IL-1β related burst inflammation . The IL-1 receptor antagonist Kineret ( Anakinra ) , seem appropriate response uncontrolled IL-1β elevation . Indeed , increase number report last year indicate good response Kineret ( Anakinra ) , colchicine-resistant FMF , also child , however , control study thoroughly evaluate efficacy safety treatment . Study outline : The study aim run FMF centre Sheba Medical Center , cover 10,000 patient . The study evaluate effect recombinant IL-1 receptor antagonist , Kineret ( Anakinra ) , frequency FMF attack patient , despite maximum tolerable dose colchicine , present one attack per month . The study design randomise , placebo-controlled , double-blind study . 50 patient randomise treatment either Kineret ( Anakinra ) , placebo treatment 4 month .</brief_summary>
	<brief_title>Kineret ( Anakinra ) , Adult Patients With Colchicine-Resistant Familial Mediterranean Fever</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>A subject must fulfil follow criterion order include study : 1 . FMF diagnose per TelHashomer criterion ( Criteria diagnosis familial Mediterranean fever . Arthritis Rheum.1998 Aug ; 41 ( 8 ) :15167Livneh A , Langevitz P , Zemer D , Zaks N , Kees S , Lidar T , Migdal A , Padeh S , Pras M ) . 2 . 1865 year age 3 . Verified mutation allele MEFV gene , thus include homozygous compound heterozygous patient 4 . Patient compliant maximum tolerable dose colchicine ( 3 mg/day ) 5 . At least one FMF attack per month chest , abdomen joint ( definition attack see ) 6 . Adequate contraception sexually active male female patient The presence follow exclude subject inclusion study : 1 . Patient pregnant enrolment visit 2 . Prior exist malignancy 3 . Active infection 4 . Manifest renal failure Creatinine clearance &lt; 30mL/min determined equation Creatinine clearance ( ml/min ) = ( 140age ) x Wight ( Kg ) /72 x serum creatinine ( mg/dcl ) For woman one multiply result 0.8 5 . Live vaccination last three month enrolment 6 . Sociopsychological state threaten compliance treatment protocol 7 . Alcohol substance abuse 8 . Concomitant medication biological antirheumatic diseasemodifying drug systemic steroid 9 . Any prior use IL1 inhibitory drug 10 . Associated disease could interfere clinical assessment : 1 . Rheumatic disorder 2 . Systemic disease , e.g . autoimmune autoinflammatory disorder , diabetes , hypertension , vasculitis , Behçet 's disease 3 . Gastrointestinal disorder , e.g . Crohn 's disease , ulcerative colitis , irritable bowel syndrome 4 . Cardiovascular disorder , e.g . post myocardial infarction , angina 5 . Pulmonary disorder , e.g . COPD , pulmonary hypertension 6 . Any condition opinion investigator make subject unsuitable inclusion 11 . Enrolment another concurrent clinical study , intake investigational drug , within three month prior inclusion study 12 . Failure refusal cooperate give instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Colchicine</keyword>
	<keyword>Anakinra</keyword>
	<keyword>FMF</keyword>
	<keyword>Colchicine resistance</keyword>
</DOC>